FIELD: medicine.
SUBSTANCE: invention refers to medicine, more specifically to oncology, and can be used to reduce the level of genotoxicity of anticancer drugs. Described is the use of a polysaccharide complex of Tussilago farfara L., consisting of rganogalacturonan I (33 %) and neutral polysaccharides (67 %), represented by the sum of arabinogalactan, rhamnane and galactoramnane, as an agent which reduces the level of DNA damage in bone marrow cells, epithelium of a thin intestine and testicles under conditions of polychemotherapy with cisplatin combined with irinotecan or cisplatin combined with paclitaxel.
EFFECT: presented is an agent reducing the level of genotoxicity of cytostatics.
1 cl, 5 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MEDICATION, REDUCING HEMATOTOXICITY OF CYTOSTATICS | 2009 |
|
RU2397774C1 |
| METHOD OF MODELING HEMOSTASIS SYSTEM DISORDERS | 2019 |
|
RU2714597C1 |
| AGENT HAVING CANCER-PREVENTIVE ACTION ON TESTICULAR CANCER AND HEREDITARY CANCER | 2023 |
|
RU2820551C1 |
| ANTIMUTAGENIC AGENT | 2019 |
|
RU2698204C1 |
| MEANS FOR CORRECTION OF VIOLATIONS IN HEMOGENESIS ERYTHROID LINEAGE CAUSED BY CYSTOSTATIC IMPACT | 2016 |
|
RU2634572C1 |
| HEMOPROTECTIVE AGENT | 2019 |
|
RU2725135C1 |
| METHOD FOR ENHANCING ANTIMETASTATIC ACTION OF CISPLATIN AND REDUCING ITS SIDE EFFECT ON HAEMOSTASIS SYSTEM | 2023 |
|
RU2825825C1 |
| HEMOPROTECTIVE AGENT | 2018 |
|
RU2696586C1 |
| PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF INTESTINAL MUCOSA INFLAMMATORY DISEASES ON THE BASIS OF LACTOBACILLUS BREVIS 47f STRAIN, MANIFESTING A LOCAL ANTI-INFLAMMATORY ACTIVITY | 2018 |
|
RU2675110C1 |
| HEMOSTIMULATING AGENT | 2017 |
|
RU2647833C1 |
